ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BMK Benchmark Holdings Plc

44.45
-0.05 (-0.11%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.11% 44.45 43.00 45.90 43.00 43.00 43.00 16,376 16:35:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 169.74M -23.15M -0.0313 -13.74 317.92M
Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 44.50p. Over the last year, Benchmark shares have traded in a share price range of 33.80p to 48.00p.

Benchmark currently has 739,352,390 shares in issue. The market capitalisation of Benchmark is £317.92 million. Benchmark has a price to earnings ratio (PE ratio) of -13.74.

Benchmark Share Discussion Threads

Showing 451 to 475 of 1100 messages
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
21/11/2016
09:33
loads of buying
larva
21/11/2016
09:06
in flight


target 105p

larva
19/11/2016
17:24
Thanks for the info Miss Womble - that could well explain the share price rise and agree that there could be more to come in the short term...

hxxps://theferret.scot/fish-farm-firm-kills-175000-salmon-accident

Good luck all :)

multibagger
19/11/2016
10:49
Yesterday's price rise in Benchmark could be the response to the disaster that befell Marine Harvest on the Isle of Skye where tons of salmon were destroyed when a delicing procedure went wrong. Could go further on Monday
miss womble
18/11/2016
16:26
4 min to grab em for weekend
onjohn
18/11/2016
15:59
being quoted 8p over the price to buy a slab



Buying 43,122 BENCHMARK HLDGS PLC ORD GBP0.001 shares
The price quoted cannot be guaranteed until the order is confirmed.
10
Price £0.838695

larva
18/11/2016
15:56
news coming
larva
18/11/2016
15:22
i remember this went from 73p to 127p last time
larva
18/11/2016
15:22
i remember this went from 73p to 127p last time
larva
18/11/2016
15:21
Fly me prettys
larva
18/11/2016
14:49
going like the clappers
onjohn
18/11/2016
14:47
getting going now


Someone bought 3 x10k


INTERESTING

onjohn
18/11/2016
14:42
Hope so - one of my higher hopes for 2017 along with HZD (CURRENT DOG!)AND WSG (SERIAL NON DELIVERER)
cumbrian2
18/11/2016
14:38
Sneaky buying

Weekend mention in Midas ? Will fly too 100p on Monday


sooooooooo good

onjohn
09/11/2016
14:29
Looks to be finally breaking out of that trading range.
phowdo
26/10/2016
06:03
Trading Statement

RNS Number : 4366N

26 October 2016

Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")

Trading Update and Notice of Results

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces that it expects Group performance for the year ended 30 September 2016 to be in line with the Board's expectations.

The integration of INVE is on plan, with the key account management programme progressing well and work on the first co-developed products has commenced.

The ongoing effect of El Niño in South East Asia and Latin America, and disease challenge coupled with low market prices in the shrimp sector, is resulting in delayed sector investment and lower growth rates in the short term in both regions. The Group intends to proceed cautiously with new investments until there is more visibility on early sales, whilst continuing to progress core infrastructure projects which support long term growth such as the state of the art vaccine facility at Braintree which is now entering the commissioning phase.

The Group is focussing on growing sales and market share in developing markets, including China, for its Breeding and Genetics and Advanced Animal Nutrition Divisions, and is actively exploring routes to market and strategic relationships in those regions.

The long term drivers of growth in the Company's sectors, which include the growing global demand for aquaculture products and an ever increasing pressure to limit the use of antibiotics in the food chain, are clearly positive. Benchmark offers an integrated package of both products and services to its customers, and they are increasingly recognising the significant value that this can deliver in terms of driving their productivity, sustainability and profitability.

Benchmark expects to announce its full year results for the 12 months to 30 September 2016 on Tuesday, 24 January 2017.

Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said:

"I am pleased to announce that the Group has delivered a solid performance in line with expectations, in a challenging but transformational year. We continue to execute our strategy to deploy world-leading technology through established distribution chains into long term growth markets, and our pipeline of products in development continues to progress well. "

multibagger
14/9/2016
10:21
If you would like to hear Malcolm Pye, Chief Executive Officer, provide an update on Benchmark he will be presenting at our next investor forum on the evening of Wednesday 28th of September. Also appearing will be the management of Venture Life Group plc and Vp plc.

To learn more about the forum and to register for free please follow this link:

Thanks,
The Equity Development team

hannahh
31/8/2016
06:20
The IP acquisition juggernaut rolls on - targetting areas of unmet need in the equine healthcare sector, which by nature is generally well resourced and customers well heeled :)


31 August 2016

RNS Reach

Benchmark Holdings plc

("Benchmark" or "the Company")

Benchmark secures innovative new equine vaccine

Benchmark is pleased to announce that its Animal Health division has entered into an agreement with Evax AG ("Evax"), a Swiss equine biotech company, to develop a recombinant vaccine to prevent and treat the most prevalent skin disease in horses, Sweet Itch, also known as Insect Bite Hypersensitivity (IBH).

Sweet Itch is caused by an allergic immune response to Culicoides midge saliva. The disease poses a significant welfare challenge for horses through intense itching and biting which causes inflammation and often breaks the skin, allowing infection to set in. It affects 7.5% of the global horse population; the estimated total market value for treatment of the disease is over GBP100 million per annum.

There is currently no efficacious preventative treatment or licensed vaccine available for controlling Sweet Itch in horses. The new vaccine utilises a Virus Like Particle technology (VLP), to which is attached a specific equine cytokine known to be implicated in this allergic disease. It combines the best of human science, cutting-edge technology and veterinary medicine to improve the quality of life of horses and horse owners. The Company expects the first commercialised product to be made available for the European, US and Canadian markets by 2020-21, followed by other markets.

Under the terms of the agreement, Benchmark will pay total consideration of GBP1.12m and is contributing up to a further GBP4m over the next 4 years towards development, which will be conducted part in-house and part externally. Evax has granted Benchmark worldwide rights for sales, distribution and manufacturing of the product (excluding Switzerland) with royalties on net sales. Manufacturing will be performed at Benchmark's state-of-the-art Braintree site.

The agreement adds a new product to the Company's vaccine portfolio and strengthens Benchmark's position to become a leader in providing veterinary allergy solutions for companion animals.

Malcolm Pye, Chief Executive of Benchmark commented:

"We are delighted to be partnering with such a highly-regarded team to develop this much needed solution for an issue which currently has no licensed vaccine treatment available. We continue to invest in cutting-edge technologies and are seeing further benefits from our investment in vaccine manufacturing at Braintree, where much of the development and all of the manufacturing for this vaccine will take place.

"Our ability to collaborate with other teams in this technology space will enhance our own offering, both in the breadth of products we can provide and in improving the efficacy of our products currently in development."

- ENDS -

multibagger
11/8/2016
06:07
Another strong addition to the IP portfolio and a new sector entry into shrimp breeding....excellent news !

Acq of South American shrimp breeding programme

RNS Number : 8788G
Benchmark Holdings PLC
11 August 2016


11 August 2016



Benchmark Holdings plc



("Benchmark" or "the Company")



Acquisition of South American shrimp breeding programme



Benchmark has entered into a technology transfer agreement under which its wholly-owned subsidiary, Genética Spring S.A.S, will secure control over aquaculture breeding programmes previously owned and operated by Centro de Investigación de la Acuicultura de Colombia Ceniacua (Ceniacua) and acquire related business, freehold land, buildings and assets, for a total consideration of $2.17m (£1.67m). Completion of the transaction is conditional upon certain legal formalities and is expected to occur before the end of August.



The acquisition adds a third species, shrimp, to Benchmark's aquaculture breeding business in salmon and tilapia, and strengthens Benchmark's position in the fast-growing shrimp industry. Benchmark has a unique opportunity to utilise the global distribution channels within its Advanced Animal Nutrition division (INVE Aquaculture), which will provide routes to market for its shrimp genetics and offer opportunities for cross-selling.



The acquired business, headquartered in Punta Canoa, near Cartagena in Colombia, operates breeding programmes for the species (L. vannamei) dominating the global shrimp sector, as well as for the marine finfish species cobia and grouper. The advanced shrimp selection programme has been particularly successful, and has bred populations with high level of resistance to certain of the major diseases affecting the shrimp industry worldwide. It is estimated that up to 40% of tropical shrimp production (>$3bn) is lost annually to disease, and according to the World Bank, production of farmed shrimp is expected to grow by 50 to 60% through to 20301.



An experienced team of world-renowned scientists will join Genética Spring as part of this transaction. The team have a long standing relationship with Benchmark's Breeding & Genetics division, and the breeding programme will continue to benefit from the advanced genetic selection services offered by Benchmark's aquaculture genetics technology business Akvaforsk Genetics Center (AFGC). This existing relationship will also ensure smooth integration of the business into the Benchmark Group.



Of the $2.17m total consideration approximately $1.33m relates to freehold land and buildings at Punta Canoa, and the balance to the breeding programme and other operational assets. Of the total consideration, US$0.35m is retained until such time as certain legal formalites related to the real estate are completed and US$0.57m is deferred, conditional upon specified operational milestones being achieved within 18 months of completion. Up to US$0.45m of the deferred consideration is payable in Benchmark shares, calculated by reference to the volume weighted average price (VWAP) of the Benchmark shares during the five business days which precede the final 3 business days prior to satisfaction of the deferred consideration. Benchmark has the option to settle this amount in cash. Management expect the acquisition to be significantly earnings enhancing from 2018.





Commenting on the acquisition, Malcolm Pye, Chief Executive of Benchmark said:



"This important acquisition strengthens our unique package of products and services that are urgently needed in the aquaculture industry today. It adds the third major aquaculture species shrimp to our already strong aquaculture breeding business in Salmon and Tilapia, and increases our market penetration into the fast-growing shrimp industry. There is strong and growing customer demand globally for disease resilient shrimp, which are more robust and deliver better yields. This acquisition provides us with very high calibre broodstock to meet that need, offering a substantial commercial opportunity for the Company and enhancing our growing reputation in aquaculture breeding and genetics."

multibagger
05/8/2016
07:14
Nice to see that I was wrong and the market has moved up :)
multibagger
05/8/2016
06:49
Agreed, the slight negative I have is their tendency to keep on the acqjuisition trail, they need to bed down. However, raising these funds at a premium is good and I have a 5 year horizon.
che7win
05/8/2016
06:37
It would be interesting to see how the market reacts as the headline is about increasing equity and diluting EPS in the short term. The good thing is that the placement is at a decent premium to current share price.

I agree that this is a very shrewd move in terms of increasing IP, getting into new areas and scalability, but won't be surprised if the share price is marked down a few pennies.

Personally, I am not too bothered, as my investment horizon is about 3-5 years - I am confident that BMK will be taken out in due course at a good premium. Till that happens, the increasing share price and possible dividends will be most welcome !

multibagger
05/8/2016
06:16
Should rise today on that news.
che7win
19/7/2016
06:22
Great RNS - strong IP and Euro 300m market potentially and more is vaccine is developed for other farmed fish species


RNS Number : 5178E
Benchmark Holdings PLC
19 July 2016

Benchmark's new seabass vaccine commences commercial field trials

Benchmark is pleased to announce that one of its new generation aquaculture vaccines has been released into the market for commercial field trials. The vaccine is the first in a series of Benchmark's new vaccines targeted at the €300m Mediterranean seabass market and aims to provide producers with an effective control of Nodavirus - a disease that impedes growth and causes high production losses. There was previously no effective treatment available for this endemic disease.

The trials will see a significant number of leading producers use the new vaccine 'on-farm' at commercial scale ahead of market authorisation, a process which typically takes 9 to 12 months.

Full development of the product has been undertaken in-house through exploiting the Group's R&D expertise, vaccine manufacturing capability and aquaculture trials facilities to ensure a streamlined and secure development process.



Nodavirus also affects several other farmed aquaculture species including Turbot, Barramundi and Grouper, and Benchmark now plans to provide these sectors with a similar solution. The development process for producing this vaccine for seabass can now be readily adapted to bring forward vaccines for these other species.

Malcolm Pye, Benchmark's CEO commented:

"This is another key milestone for Benchmark and is testament to our increased capability, as we continue to invest in our manufacturing capacity and technology, to open up new markets for the company by solving major challenges for our customers. This product represents a significant first for the Company, as the full development process including research, design, development and manufacturing, has been delivered entirely in-house by our specialist teams."

multibagger
15/7/2016
17:17
Yeah strong sign of confidence - could be a inter-fund trade. I recall some big trades around the 22nd of June as well that I commented on either on this thread or on LSE. (Edit: 24m approx traded in big deals on that day)

Re the Equity Development presentation..... The most interesting part for me was the pipeline and stages at which various products were in development. I particularly like the business model and the way that the divisions interlink synergestically. The Directors have decent skin in the game and I think that the move into tilapia and shrimp will generate a lot of revenue from the developing economies.

Apart from all this, the current market price offers a good margin of safety compared to placing price. I have taken a little over 154k shares so far and intend to hold for a minimum of 3-5 years for starters. This time frame is likely to be transformational and I would not rule out the possibility of a takeover by a food giant at a good premium to where we are now.

Good luck all :)

multibagger
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older

Your Recent History

Delayed Upgrade Clock